The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

On Friday, Boston Scientific Corporation (BSX) stock saw a decline, ending the day at $86.99 which represents a decrease of $-0.60 or -0.69% from the prior close of $87.59. The stock opened at $87.12 ...

AVVIGO is an intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system designed to provide high-quality IVUS ...

Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...

Very lucky to have with us Boston Scientific. We've got the Head of Investor Relations, Jon Monson. Somewhere out there, we have the Head of the EP business, Nick Spadea-Anello. Did I pronounced ...

On Thursday, Boston Scientific Corporation (BSX) stock saw a decline, ending the day at $87.59 which represents a decrease of $-1.18 or -1.33% from the prior close of $88.77. The stock opened at ...

Shares of Boston Scientific Corp. BSX shed 0.69% to $86.99 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.32% to 5,870 ...

As of 11:40 AM EST. Market Open. Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX ...